Pfizer, Germany agree on prices for Bosulif, Xalkori

Pfizer Inc. (NYSE:PFE) and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) in a joint statement said they reached an agreement on prices for cancer drugs Bosulif bosutinib and Xalkori crizotinib. The deal for Bosulif comes a month after Pfizer said it would withdraw the product from the German market because there was "no prospect of reaching an agreement" on the Orphan drug's price after the first round of negotiations. Pfizer and GKV-Spitzenverband could not be reached for details on the negotiated prices. In October, Germany's Federal Joint Committee (G-BA) said Bosulif has an "unquantifiable" additional benefit for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) -- the indication for which the dual inhibitor of BCR-ABL and Src kinase has conditional approval in the EU (see BioCentury Extra, Nov.15). ...